T:+44 (0) 1223 497700  |  E: info@sareum.co.uk

Developing next generation kinase inhibitors for autoimmune disease & cancer.

*Molecular structure of TYK2 kinase (blue) and a prototype inhibitor (gold)

SCROLL DOWN

Welcome to Sareum.

Sareum is a clinical-stage small molecule company actively involved in developing next-generation kinase inhibitors to treat autoimmune diseases and cancer.

We recognise the crucial role of the TYK/JAK kinase cell signalling family in maintaining a healthy immune system, and our pipeline is primarily focused on this area of scientific and commercial interest.

Scientist using a microscope and writing something down
A group of men sat around having a meeting

About
Sareum.

We are committed to advancing molecules in the TYK2/JAK1 space. Our focus on this dual JAK kinase inhibition is due to the potential superior efficacy we believe this offers compared to agents targeting just one of these kinases.

Research &
development.

We are focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential.

Investor
relations.

View our share price, latest results and reports, regulatory news and sign up to email alerts.

Latest developments.

Company highlight.

“We are encouraged by the preliminary data from the single ascending dose and food effect parts of the Phase 1a trial for SDC-1801, which support our confidence in the trial and the broader clinical strategy.”

Tim Mitchell PhD – Founder and CEO